Avalo Therapeutics opened lower at $8.29, compared with its previous close of $8.51. In the last trading session, the stock traded between $7.54 and $8.39. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Avalo Therapeutics is now worth
$ 0.12
Resulting in a loss of
$ 99.88 (99.88%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.83 (-9.69%)
Day High
$8.39
Day Low
$7.54
Day Open
$8.29
Prev Close
$8.51
Volume
26,78,863
1W Return
8.76%
1M Return
-41.98%
3M Return
-60.53%
6M Return
-62.05%
1Y Return
-50.42%
Market Cap ($ Mn)
444
PE Ratio
-
PB Ratio
2.31
PEG Ratio
-
ROE
-73.16%
ROCE
-67.07%
EPS (TTM)
$-0.35
1 Week
8.76%
1 Month
-41.98%
3 Months
-60.53%
6 Months
-62.05%
9 Months
-46.45%
Wedbush maintains Outperform on Avalo Therapeutics, cuts target to $20
Wedbush maintains an Outperform rating on Avalo Therapeutics. Price target reduced from $22 to $20 by analyst Robert Driscoll. No change to the investment rating despite the lower price objective.
6 days agoAvalo Therapeutics Q3FY26 Results: Net loss narrows to $18.9M, cash at $462.8M
Net loss narrowed to $18.9 million in Q3 2026 from $30.6 million in Q3 2025. Cash, cash equivalents, and investments stood at $462.8 million as of September 30, 2026. R&D expenses increased $1.4 million YoY to $15.0 million due to manufacturing activities. G&A expenses rose $2.8 million YoY to $8.4 million driven by stock-based compensation. Phase 3 program initiation for abdakibart planned for first half of 2027.
7 days agoAvalo Therapeutics to participate in two investor conferences in November
Management will participate in fireside chats at two major healthcare conferences in November 2026. The Guggenheim Healthcare Innovation Conference appearance is scheduled for November 9 at 8:30 am ET. The Stifel 2026 Healthcare Conference appearance is scheduled for November 10 at 2:00 pm ET. Webcast replays will be available on the investor relations website for at least 30 days.
10 days agoAvalo Therapeutics grants 101,600 stock options to new employees
Granted 101,600 stock options to three new employees. Exercise price set at $15.47 per share. Awards comply with Nasdaq Listing Rule 5635(c)(4). Vesting begins 25% after one year, then monthly.
1mo agoAvalo Therapeutics to present Phase 2 hidradenitis suppurativa data at EADV 2026
Avalo Therapeutics will present Phase 2 LOTUS trial data for abdakibart at the EADV Congress 2026 in Vienna. A late-breaker oral presentation on October 1, 2026, will detail Week 16 efficacy and safety results. Abdakibart targets the IL-1β pathway for moderate to severe hidradenitis suppurativa, affecting 1-4% of the global population. The company is advancing abdakibart into a Phase 3 registrational program while developing AVTX-010.
1mo agoAvalo Therapeutics grants 78,000 stock options to six new employees
Granted 78,000 stock options to six new employees as inducement awards. Exercise price set at $19.34 per share, equal to closing price on Sept. 2, 2026. Awards vest 25% after one year and monthly over the next 36 months. Grants approved under Nasdaq Listing Rule 5635(c)(4).
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Avalo Therapeutics is now worth
$ 0.12
Resulting in a loss of
$ 99.88 (99.88%)
Note: Past profits do not guarantee future returns.
